Pharmaceuticals

Innovation-Led Developments Influencing the Aurora Kinase B Market

March 18, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Aurora Kinase B Market Across 2026–2030?

The aurora kinase b market has witnessed substantial rapid growth in recent years. This market is projected to expand from $1.27 billion in 2025 to $1.43 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.0%. Historically, this expansion can be linked to advancements in molecular oncology research, the identification of aurora kinase b as a cancer target, the broadening of clinical trial infrastructure, increasing investment in targeted cancer therapies, and progress in kinase inhibitor development.

The aurora kinase b market is anticipated to experience substantial expansion in the coming years, projected to reach $2.22 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. This significant growth in the forecast period is primarily driven by factors such as a heightened demand for precision cancer therapeutics, the broadening adoption of personalized medicine approaches, an uptick in oncology clinical trial activity, increased investments in novel kinase inhibitors, and improved regulatory support for targeted oncology drugs. Furthermore, major trends expected during this period include the intensified development of selective aurora kinase b inhibitors, a growing emphasis on combination oncology therapies, the expansion of precision oncology drug pipelines, an increasing focus on mitotic targeted therapies, and better biomarker-based patient stratification.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Aurora Kinase B Market?

The increasing occurrence of cancer is projected to boost the expansion of the aurora kinase B market in the foreseeable future. Cancer refers to a collection of illnesses marked by the uncontrolled multiplication and dispersion of atypical cells, which can infiltrate nearby tissues and spread to other parts of the body. The escalation in cancer cases stems from factors like an aging demographic, shifts in lifestyle, exposure to environmental hazards, and enhanced detection and diagnostic methods. Aurora kinase B is vital for mitosis, and its excessive expression is associated with chromosomal instability and the advancement of cancer. Given its involvement in the division of tumor cells, it is frequently a target in cancer treatments. For example, in February 2024, the World Health Organization, an intergovernmental body based in Switzerland, reported approximately 20 million new cancer cases in 2022, alongside 9.7 million fatalities. Projections indicate that by 2050, new cancer cases will surpass 35 million, signifying a 77% surge from 2022 levels. Consequently, the growing prevalence of cancer is propelling the development of the aurora kinase B market.

What Segmentation Levels Are Considered In The Aurora Kinase B Market?

The aurora kinase b market covered in this report is segmented –

1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types

2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications

3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811

2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies

3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib

4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies

5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials

6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology

What Trends Are Projected To Affect The Aurora Kinase B Market?

Leading companies within the aurora kinase B market are advancing innovative products, such as aurora kinase inhibitors, with the goal of specifically targeting and disrupting crucial processes involved in cell division. These inhibitors are medications designed to block the activity of Aurora kinases, which are essential for cell division, thereby impeding the proliferation of cancer cells and potentially reducing tumor growth. For instance, in June 2023, Ellipses Pharma, a UK-based biotechnology company, announced the U.S. Food and Drug Administration (FDA) approval for its EP0042, a dual FLT-3 and Aurora kinase inhibitor. EP0042 is currently under development as a treatment for acute myeloid leukemia (AML) and functions by inhibiting both FLT3 and Aurora kinase. This approach is specifically tailored for AML patients who have developed resistance to FLT3 inhibitors. Research has indicated that the dual inhibition of FLT3 and Aurora kinase can overcome acquired resistance to selective FLT3 inhibition in both in vitro and in vivo studies.

Which Leading Firms Are Contributing To The Growth Of The Aurora Kinase B Market?

Major companies operating in the aurora kinase b market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc

Read the full aurora kinase b market report here:

https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report

Which Regions Are Projected To Dominate The Aurora Kinase B Market In The Coming Years?

North America was the largest region in the aurora kinase B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Aurora Kinase B Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20496&type=smp

Browse Through More Reports Similar to the Global Aurora Kinase B Market 2026, By The Business Research Company

Cancer Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Skin Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Pancreatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795